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Abstract: Obesity, a characteristic of metabolic syndrome, is also associated with chronic inflam-
mation and the development of autoimmune diseases. However, the relationship between obesity
and autoimmune diseases remains to be investigated in depth. Here, we compared hepatic gene
expression profiles among high-fat diet (HFD) mice using the primary biliary cholangitis (PBC)
mouse model based on the chronic expression of interferon gamma (IFNγ) (ARE-Del-/- mice). The
top differentially expressed genes affected by upstream transcriptional regulators IFNγ, LPS, and
TNFα displayed an overlap in HFD and ARE-Del-/- mice, indicating that obesity-induced liver
inflammation may be dependent on signaling via IFNγ. The top pathways altered in HFD mice
were mostly involved in the innate immune responses, which overlapped with ARE-Del-/- mice. In
contrast, T cell-mediated signaling pathways were exclusively altered in ARE-Del-/- mice. We further
evaluated the therapeutic effect of luteolin, known as anti-inflammatory flavonoid, in HFD and ARE-
Del-/- mice. Luteolin strongly suppressed the MHC I and II antigen presentation pathways, which
were highly activated in both HFD and ARE-Del-/- mice. Conversely, luteolin increased metabolic
processes of fatty acid oxidation and oxidative phosphorylation in the liver, which were suppressed
in ARE-Del-/- mice. Luteolin also strongly induced PPAR signaling, which was downregulated
in HFD and ARE-Del-/- mice. Using human GWAS data, we characterized the genetic interaction
between significant obesity-related genes and IFNγ signaling and demonstrated that IFNγ is crucial
for obesity-mediated inflammatory responses. Collectively, this study improves our mechanistic
understanding of the relationship between obesity and autoimmune diseases. Furthermore, it pro-
vides new methodological insights into how immune network-based analyses effectively integrate
RNA-seq and microarray data.
Keywords: IFNγ; obesity; autoimmune diseases; Th1; luteolin; high-fat diet; RNA-seq; microarray;
bioinformatics; animal study
1. Introduction
Interferon gamma (IFNγ), the only characterized Type II interferon, is an inflammation
modulator regulating both pro- and anti-inflammatory responses. IFNγ is predominantly
produced by natural killer (NK) cells and natural killer T cells during the innate immune
response and by CD4+ T helper (Th1) cells and CD8+ cytotoxic T cells in the humoral
immune response. Furthermore, emerging evidence shows that other cell types, including
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macrophages, dendritic cells, and neutrophils, also produce IFNγ in a context-dependent
manner. IFNγ expression is critical for the initial host innate immune response and is
also essential to mount an adaptive immune response. Several reports have shown that
serum IFNγ is increased in patients with autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) [1]. Corresponding to this data, IFNG
polymorphisms are associated with susceptibility to these diseases in patient cohorts [2,3].
Aberrant IFNγ expression was observed in other autoimmune disease murine models,
including experimental autoimmune encephalomyelitis and collagen-induced arthritis, in
both protective and detrimental roles [4].
Primary biliary cholangitis (PBC) is an autoimmune disease of the liver, predominantly
affecting middle-aged women but having a worse prognosis in men, which eventually
leads to liver failure [5]. PBC is characterized by progressive destruction of the bile ducts
in the liver, caused by autoreactive T cell-mediated self-attack on the biliary epithelial cells.
Incidence of PBC is gradually increasing worldwide, but there is as of yet no cure, leaving
liver transplantation as the sole treatment option in later stages. Previously, we reported
that a mouse model (ARE-Del-/-), characterized by chronic expression of IFNγ, has strong
serological, and pathological phenotypes of PBC [6]. These include portal inflammation,
bile duct damage, positive anti-mitochondrial antibodies (AMAs, >95% positive in patients
with PBC), and increased serum bile acid with disease progression. This mouse model
was noted to be a powerful new research tool, as it strongly reflected clinical features of
female-prevalent autoimmune diseases [7,8]. ARE-Del-/- mice with chronic low expression
of IFNγ are generated by genetic deletion of the AU-rich element (ARE) in the 3’-UTR
region of IFNG. Given that PBC is thought to be a Th1-mediated autoimmune disease, our
findings support a primary role for IFNγ in the development of PBC.
Over the last few decades, obesity has become a major research interest due to its dra-
matic increase worldwide and the clinical and economic burden of obesity-related diseases.
Obesity-related inflammatory responses are associated with adipokines secreted by adipose
tissue, which function as hormones and cytokines to modulate inflammatory responses and
metabolic processes [9]. Recent emerging views indicated a potential relationship between
obesity and major autoimmune diseases such as SLE, RA, multiple sclerosis, and type
1 diabetes [10–13]. However, the underlying mechanisms that connect these conditions
remain to be elucidated. Leptin is an adipokine, primarily secreted by adipocytes, and
is considered a key regulator of inflammatory responses and metabolic processes [14].
Here we characterize the central pathogenic role of IFNγ in HFD-induced inflammatory
responses. Our data provide new insight into the mechanism of the interaction between
IFNγ and leptin signaling, which furthers our understanding of the relationship between
obesity and the development of Th1-mediated autoimmune diseases.
2. Results
2.1. Comparison of Top Regulators and Pathways between High-Fat Diet (HFD) and ARE-Del-/- mice
We compared the top upstream transcriptional regulators in both HFD and ARE-
Del-/- mice. The top upstream regulators in HFD mice were determined to be IFNγ
(p = 9.19 × 10−24), TLR4 (p = 5.43 × 10−23), and TNF (p = 1.04 × 10−21) (Table 1). These
transcriptional regulators overlapped with those in ARE-Del-/- mice, as previously re-
ported [6]. These data indicate that IFNγ signaling plays a critical role in HFD-induced
inflammatory responses. We further characterized top pathways altered in HFD mice, and
compared these pathways in ARE-Del-/- mice (Figure 1). The top 20 altered pathways in
ARE-Del-/- mice are listed in Figure 1A. The top differential pathways in HFD mice were
aligned and compared with those in ARE-Del-/- mice (Figure 1B). It was notable that T
cell-mediated responses were mostly detected in ARE-Del-/- mice, but not in HFD mice. In
the same way, we aligned the altered pathways in ARE-Del-/- mice according to the top
20 canonical pathways in HFD mice (Figure 1C,D). These data show that innate immune
responses were among the top pathways altered in HFD mice (Figure 1C), which were also
strongly activated in ARE-Del-/- mice (Figure 1D). Overall, there were robust similarities
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among the top upstream regulators and pathways between HFD and ARE-Del-/- mice,
suggesting that a HFD can aggravate the pathological development of PBC. Importantly,
HFD mice display IFNγ-induced early innate inflammatory responses, whereas ARE-Del-/-
mice display more advanced adaptive immune responses.
Table 1. The top upstream transcriptional regulators in high-fat-diet mice, determined by the
Ingenuity® Knowledge Base.
Top Regulators p-Value
1 IFNγ 9.19 × 10−24
2 TLR4 5.43 × 10−23
3 TNF 1.04 × 10−21
Fisher’s exact test p-values are calculated based on the overlap between the dataset genes and genes
regulated by the appropriate transcriptional regulator.
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Figure 1. The comparison of altered pathways betwee high-fat-diet and ARE-Del-/- mice. (A) The top 20 alt red pathways
in ARE-Del-/- mice. Yellow marks represent pathways specifically increased in ARE-Del-/- mice compared tohigh-fat-diet
mice; (B) Overlapping pathways of high-fat-diet mice were aligned with those in (A); (C) The top 20 altered pathways in
high-fat-diet mice; (D) Overlapping pathways of ARE-Del-/- mice were aligned with those in (C). Ratio (bottom y-axis, red
line) refers to the number of genes from the dataset divided by the total number of genes that make up that pathway from
within the ingenuity pathway analysis (IPA) knowledge base. The -log of the p-value (top y-axis, bar) was calculated by
Fisher’s exact test.
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2.2. The Therapeutic Effect of Luteolin on the Early Development of PBC
In a previous study, luteolin improved insulin resistance and hepatic steatosis by
suppressing hepatic lipogenesis and lipid absorption in a HFD mouse model [15]. Given
that IFNγ-mediated immune responses play a primary role in HFD-induced inflamma-
tory responses, we further characterized the immune responses in HFD mice by treating
these mice with luteolin. Luteolin is a natural flavonoid present in various fruits and
vegetables, and many studies have shown that it possesses anti-oxidant, anti-cancer, and
anti-inflammatory effects [16]. However, it is not yet understood how luteolin modulates
immune responses in terms of these therapeutic effects. In Table 2, we compared the top 20
altered pathways in HFD mice with those altered after luteolin treatment and ARE-Del-/-
mice. Although similar pathways were activated in HFD and ARE-Del-/- mice, luteolin
downregulated these pathways in HFD mice, implying that it may also suppress early
inflammatory responses in ARE-Del-/- mice.
Table 2. Suppressive effects of luteolin treatment on the top 20 altered pathways in high-fat-diet mice.
Top 20 Canonical Pathways in HFD Mice HFD ARE Lut
1 Fcγ Receptor-Mediated Phagocytosis in Macrophages and Monocytes up up down
2 Leukocyte Extravasation Signaling up up down
3 Phagosome Formation up up down
4 Granulocyte Adhesion and Diapedesis up up down
5 Natural Killer Cell Signaling up up down
6 IL-10 Signaling up up -
7 Dendritic Cell Maturation up up down
8 Atherosclerosis Signaling up up down
9 Production of Nitric Oxide and Reactive Oxygen Species in Macrophages up up down
10 PI3K Signaling in B Lymphocytes up up -
11 TREM1 Signaling up up down
12 Hepatic Fibrosis/Hepatic Stellate Cell Activation up up down
13 Altered T cell and B cell Signaling in Rheumatoid Arthritis up up down
14 Agranulocyte Adhesion and Diapedesis up up down
15 Communication between Innate and Adaptive Immune Cells up up down
16 CCR5 Signaling in Macrophages up up down
17 Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses up up down
18 Toll-like Receptor Signaling up up down
19 Role of NFAT in Regulation of the Immune Response up up down
20 B Cell Receptor Signaling up up down
HFD, high-fat-diet mice; ARE, ARE-Del-/- mice; Lut, HFD with luteolin treatment.
2.3. Luteolin Modulates Antigen Presentation and Energy Metabolic Pathways
We previously reported that chronic expression of IFNγ activated the antigen presenta-
tion pathway in the liver [6]. This indicates that early inflammatory response in ARE-Del-/-
mice also had a strong induction of antigen presentation pathways, including increased
expression of MHC class I and II molecules. Consistent with this, gene set enrichment anal-
ysis (GSEA) profiles showed that HFD mice displayed positive regulation of MHC I and II
expression, while these expressions were suppressed upon luteolin treatment (Figure 2A).
Given that IFNγ is critical for antigen presentation in innate immune responses, and IFNγ
is also important for primary inflammatory signaling in HFD mice, this result suggests that
luteolin ameliorates inflammatory responses in the innate immune system, possibly via
suppression of IFNγ signaling pathway.
Int. J. Mol. Sci. 2021, 22, 208 5 of 14
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Figure 2. ene Set Enrichment Analysis (GSEA) of antigen presentation pathways (A) and metabolic
pathways (B) in high-fat-diet mice with/without luteolin treatment. (A) Expression of MHC-I and
MHC-II gene sets in high-fat-diet mice with and without luteolin treatment; (B) Expression of FAO
and Oxphos gene sets in high-fat-diet mice with and without luteolin treatment. FDR, false discovery
rate; FWER, family wise error rate; NES, normalized enrichment scores.
We also analyzed changes in metabolic pathways, such as fatty acid oxidation (FAO)
and oxidative phosphorylation (Oxphos). Emerging evidence suggests that immune cells
such as macrophages and dendritic cells switch metabolic pathways to modulate their pro-
as well as anti-inflammatory responses [17,18]. HFD mice displayed negative regulation
of the FAO and Oxphos pathways as determined by hepatic gene expression (Figure 2B).
At the same time, FAO and Oxphos pathways were strongly induced in HFD mice upon
luteolin treatment. Even though these data represented changes in global hepatic gene
expression in HFD mice, important information can still be gleaned about the potential
effects of luteolin on the metabolic switch in immune cells.
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2.4. HFD Dysregulates Macrophage Function, Possibly via the IFNγ Signaling Pathway
There were 269 upregulated genes in the liver of HFD mice, of which macrophages
are one of the top cell phenotypes, according to the ARCHS4 database and Mouse Genome
Informatics (MGI) database resources, and as characterized by Enrichr pathway analysis
(Figure 3A). Other characterized cell phenotypes included innate immune cells, such as
dendritic cells, plasmacytoid dendritic cells, and neutrophils (Figure 3B). These data sup-
port the previous conclusion that HFD-induced inflammation is involved in the innate
immune response, particularly via macrophage immunomodulation. Notably, the HFD
increased dysregulated macrophage function, including abnormal macrophage physiol-
ogy and impaired macrophage phagocytosis according to the MGI database resources
(Figure 3C). This is consistent with our previous report that IFNγ altered macrophage func-
tion and impaired autophagy [19], which can lead to impaired macrophage phagocytosis.
These data reveal that the IFNγ signaling pathway in HFD mice plays a critical role in
macrophage function.
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Figure 3. Pathway analysis of upregulated genes in the liver of HFD mice. (A) Abnormal macrophage
function predicted by pathway analysis based on ARCH4 and MGI phenotypes databases; (B) The
top 10 upregulated ph notyp according to the ARCH4 d tabase; (C) A cluster graph f gene
expression profiles of abnormal macrophage physiology and impaired macrophage phagocytosis in
the MGI phenotypes database.
2.5. Luteolin Activated Nuclear Receptor (NR) Signaling Pathways, Including LXR, RXR, and
PPAR
Given that NR signaling, including the LXR, RXR, and PPAR signaling pathways,
were suppressed in ARE-Del-/- mice [19], we further analyzed 64 downregulated genes in
the liver of HFD mice. The top pathways associated with these significantly downregulated
genes were defined according to the Chromatin Immunoprecipitation (ChIP) Enrichment
Analysis (ChEA; 2016) and Mouse Gene Atlas databases (Figure 4A). Interestingly, our
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data indicated that brown adipocyte gene expression was significantly downregulated
(p = 1.9 × 10−8) in the liver of HFD mice, correlating with downregulated nuclear RXR,
PPARγ, LXR, CLOCK, PPARα, and EGR1 signaling. The related genes in these NR signaling
pathways are presented in a cluster graph in Figure 4B. Since luteolin is known to be a
partial antagonist of PPARγ [20], we further compared PPAR signaling in HFD mice to
HFD mice treated with luteolin using GSEA Pre-ranked analysis (Figure 4C). The GSEA
profiles showed that the expression pattern of PPAR signaling was downregulated in the
liver of HFD mice. In contrast, luteolin treatment significantly upregulated genes related to
the PPAR signaling pathway in the liver of HFD mice, supporting that luteolin may be an
agonist of both PPARα and PPARγ.
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Figure 4. Pathway analysis of downregulated genes in the liver of HFD mice. (A) Downregulated
NR signaling pathways and genes associated brown adipose tissue based on ChEA and Mouse
Gene Atlas database; (B) A cluster gr ph of gene expression profiles of dow regulated NR signaling
according to ChEA database; (C) GSEA profiles of PPAR signaling in HFD with and without luteolin
treatment.
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2.6. Interaction between IFNγ and Obesity-Related Genes
To characterize the genetic interaction between IFNγ and obesity-related genes, we
identified the 53 most significant variants (p ≤ 1 × 10−5), selected by the National Human
Genome Research Institute GWAS catalog. Among these genes, 47 have known direct or
indirect interactions with IFNγ (Figure 5). Using the pathway explorative analysis tool
of ingenuity pathway analysis (IPA) software, we identified two genes, TNFA and UBC
(Ubiquitin C), that maximize the connection between obesity-related genes and IFNγ. As
shown in Table 1, TNFα signaling was one of top upstream transcriptional regulators in
the liver of HFD mice, implying that IFNγ- and TNF-mediated inflammatory responses
are major events in obesity-associated chronic inflammation. Although the functional role
of UBC has not been well characterized because deletion of this gene results in embryonic
lethality due to its requirement for fetal liver development [21], the genetic deletion of UBB,
another gene encoding mammalian ubiquitin (Ub) protein, induced adult-onset obesity
in mice [22]. This data yields new clues as to the potential role of UBC in obesity and
obesity-associated inflammatory responses.
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3. Discussion
Excessive lipid accumulation in obesity has been linked to the release of detrimental
cytokines and chemokines that result in metabolic dysregulation. In obese humans with a
body mass index over 30, pro- and anti-inflammatory cytokines are upregulated, including
IL-5, IL-10, IL-12, IL-13, IFNγ, and TNFα [23]. Although obesity is known to have a com-
ponent of low-grade, systemic inflammation, the relationship between obesity-associated
inflammation and autoimmune diseases remains to be elucidated. The mouse model
of autoimmune diseases used here displays chronic expression of IFNγ via the genetic
modification of the AU-rich element in the 3′-UTR of IFNG mRNA [24]. Notably, the top
upregulated transcriptional regulators in the liver of both HFD and ARE-Del-/- mice dis-
played an overlap, suggesting that IFNγ may be a primary cytokine in obesity-associated
inflammatory responses. These data also imply that the chronic expression of IFNγ in
obesity aggravates Th1-mediated autoimmune diseases. In this analysis, we compared
male HFD mice to female ARE-Del-/- mice. As reported previously, ARE-Del-/- mice
have female-biased pathological and serological phenotypes of PBC, and the prevalence in
females is a hallmark of major autoimmune diseases [25]. Considering that female mice
have a strong sensitivity to Th1-mediated inflammatory responses, we hypothesized that
female HFD mice would have more interesting pathological phenotypes compared to male
HFD mice. Collectively, our data support the primary role for IFNγ in linking obesity to
the development of autoimmune diseases.
There are remarkable differences in the upregulated inflammatory responses between
HFD and ARE-Del-/- mice, even though IFNγ is a common primary regulator in these con-
ditions. HFD mice display early IFNγ-mediated innate inflammatory responses, whereas
ARE-Del-/- mice have greater adaptive immune responses, such as activation of T helper
cells and associated signaling pathways. In ARE-Del-/- mice, the low but chronic ex-
pression of IFNγ induced distinct pathological phenotypes similar to PBC [6], and early
IFNγ-mediated inflammation was involved in the activation of the innate immune sys-
tem, triggering antigen presentation signaling pathways [6]. In HFD mice, the low but
chronic expression of IFNγ may stimulate early innate immune responses similar to those
in ARE-Del-/- mice, depending on the local and systemic levels of IFNγ. As previously
reported, beyond a certain threshold, IFNγ breaks the immune tolerance which induces
autoreactive B and T cells to attack self-epitopes in specific cells and organs, leading to
autoimmune diseases [19]. Therefore, obesity-induced IFNγ signaling can be aggravated
by infectious, genetic and environmental factors to break this immune tolerance barrier in
the host immune system.
In adipocytes, IFNγ inhibits PPARγ-mediated gene expression by not only suppress-
ing protein synthesis, but also increasing protein degradation of PPARγ [26]. The polyubiq-
uitination of PPARγ is regulated by IFNγ pathways dependent on serine phosphorylation
of PPARγ. Therefore, IFNγ regulates PPARγ expression, while PPARγ also directly regu-
lates IFNγ expression. The PPARγ agonist thiazolidinedione rosiglitazone (Ro) suppresses
expression of IFNγ target genes in macrophages [27]. Conversely, the PPARγ antagonist
GW9662 increases lymphocyte IFNγ expression, and PPARγ ligands modulate expression
at the IFNγ promotor, indicating that PPARγ negatively regulates the IFNγ promoter [28].
Collectively, these data suggest that PPARγ and IFNγ reciprocally suppress their activi-
ties, which may be a central regulatory node to modulate lipid metabolic pathways and
Th1-mediated inflammatory responses.
Obesity increases the infiltration of macrophage in adipose tissue, and induces se-
cretion of several inflammatory mediators [29]. Increased expression of IFNγ and TNFα
are classified as markers of pro-inflammatory (M1) rather than anti-inflammatory (M2)
polarization in macrophages [30]. Given that IFNγ and TNFα were determined to be
top transcriptional regulators in HFD mice, it is likely that M1 macrophages are strongly
activated in obesity. Metabolically, M2 macrophages are more dependent on oxidative phos-
phorylation, the dramatic switch to which results in phenotypic and functional changes
in macrophages [31]. Moreover, upregulated genes in HFD mice indicated activation of
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microphages as well as dysregulation of macrophage functions. Similar to this, chronic
expression of IFNγ in ARE-Del-/- mice induced abnormal macrophage function, such as
defective autophagy, which has been linked to dysregulated lipid metabolism through
altered NR signaling [19]. The macrophage is a primary cell type in the formation of most
granulomas, where immune cell aggregates form in response to chronic inflammatory stim-
uli such as Mycobacterium tuberculosis infection [32]. Considering that granuloma formation
is a pathophysiological phenotype in both PBC and ARE-Del-/- mice, these data suggest
that dysregulated lipid metabolism in macrophages via altered NR signaling pathways
may play a critical role in granuloma formation as well as obesity-associated pathology.
One of the most recognized adipokines, leptin, is a key molecule in the interplay
between energy metabolism homeostasis and metabolism-linked inflammatory responses.
Leptin is involved in the JAK/STAT pathway along with IFNγ, and acts synergistically with
IFNγ-mediated inflammatory responses [33]. In contrast, alternative p38, ERK, JNK, PKC,
and PI3K/AKT pathways overlap in signaling via both leptin and IFNγ receptors [34–37].
IFNγ binding to its specific receptor activates JAK1/JAK2, resulting in dimerization of
STAT1, which acts as a transcription factor to induce IFNγ response genes. In contrast, lep-
tin binding to its receptor induces phosphorylation of JAK2, which subsequently activates
STAT3 via dimerization.
Given that JAK2 plays a critical role in brown adipose tissue function and diet-induced
thermogenesis in HFD mice [38], JAK2 signaling between leptin and IFNγ may play a
critical role in obesity-related inflammation and metabolic disorders. Dimerized STAT3 acts
as a transcription factor and upregulates SOCS3 expression, which can induce hypothalamic
leptin resistance linked to obesity [39,40]. As we demonstrated previously, female ARE-
Del-/- mice specifically induced SOCS3 gene expression in the liver, inhibition of which
correlates with the activation of alternative pathways, such as PI3K/AKT [41]. It has
also been reported that IFNγ induces SOCS3 expression, which further inhibits STAT3
phosphorylation in endothelial cells, implying that IFNγ can desensitize liver cells to leptin
signaling via the SOCS3-mediated inhibition of STAT3 [42]. Taken together, the signaling
interaction between leptin and IFNγ, particularly in adipose tissue of obese individuals,
may play a key modulating role in obesity-associated metabolic disorders and development
of pathology.
Here, we demonstrated a potential therapeutic effect of luteolin in the early pathogenic
development of PBC, as well as in other Th1-mediated autoimmune diseases. Luteolin
(3′,4′,5,7-tetrahydroxyflavone) has been thought to have beneficial anti-cancer, anti-oxidant,
and anti-inflammatory effects [43–45]. However, the mechanisms by which these beneficial
effects occur have not been elucidated. Luteolin inhibits antigen-specific IFNγ production
in autoreactive T cells in vitro [46], indicating that luteolin has a suppressive effect on IFNγ
production through the adaptive immune response. Our data support the suppressive role
luteolin in IFNγ signaling, but also reveal that luteolin can suppress early IFNγ-induced
innate immune responses, possibly via NR signaling, by particularly enhancing the PPAR
signaling pathway. Luteolin not only suppressed MHC I and II class antigen presentation
pathways, but also modulated FOA and Oxphos metabolic pathways, which are critical for
functional and phenotypical changes in macrophages. This luteolin-mediated metabolic
change may be a key regulatory mechanism to suppress early IFNγ-mediated inflammatory
reaction in the livers of HFD mice.
Additionally, these data demonstrate that immune network-based analysis can effi-
ciently integrate different platforms or technologies that measure gene expression analysis.
Since RNA-sequencing emerged last decade as a more robust and reproducible analysis
tool than previous commonly used gene expression arrays [47], it has often been required to
compare gene expression profiles generated by these two different technologies. However,
comparison of differentially expressed genes (DEGs) identified in these different platforms
is not possible, as the datasets are incompatible with each other, even when generated from
the same biological condition. Given that immune responses are prompt, and gene sets
are simultaneously activated, immune network-based analysis can be consistent and inde-
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pendent of different gene expression analysis platforms. Therefore, this methodological
approach can be further used for the analysis of immune responses to compare mechanisms
as well as the drug repurposing. Immune network-based analysis, as shown here, was
used to predict the therapeutic effect of luteolin in the early stages of PBC pathogenesis.
4. Materials and Methods
4.1. Data Source
GSE76309 and GSE54189 datasets were obtained from the GEO database (http://
www.ncbi.nlm.nih.gov/geo/). In the GSE76309 dataset [6], mRNA was isolated from the
liver of ARE-Del-/- mice and analyzed by Illumina HiSeq2500 sequencing with TruSeq v4
chemistry. BAM files were generated by Tophat (v2.0.8), aligned to the mouse reference
genome mm9 and ensemble v70 transcripts. Each BAM file was uploaded into Partek
Genome Studio 6.6 to identify DEGs. The GSE54189 dataset [15] includes gene expression
profiles of adipose tissue and liver from C57BL/6 mice, the same genetic background as
ARE-Del-/- mice [24]. This dataset contains array-based gene expression analyses using
Illumina Mouse WG-6 v2 Expression BeadChips (Illumina, San Diego, CA, USA). Further
data analysis was performed with ArrayAssist software (Stratagene, La Jolla, CA, USA)
using Bioconductor.
4.2. Gene Set Enrichment and Pathway Analysis
Although GSEA and IPA are commonly used to characterize biological functions of
gene expression profiles, the difficulty lies in selecting the appropriate comparison dataset
and pathways from among an ever-increasing collection of datasets. As immune responses
are often dynamically regulated by posttranslational modification [48,49], knowledge-based
analysis is essential in order to characterize the immune network in human diseases as
performed in this research. For GSEA, we downloaded target gene sets from the Molecular
Signatures Database (MSigDB). The ranked experimental gene was listed along with the
enriched gene sets. For IPA, statistically significant DEGs were tested using knowledge-
based datasets. Z-score, ratio, and p-value were calculated to define the significance of a
gene functioning in a network, as well as intergenic relationships. p-value was calculated
using the right-tailed Fisher’s exact test, and a p-value less than 0.05 signified statistical
significance and nonrandom association.
5. Conclusions
These data provide new insights into the mechanistic understanding of obesity-
associated inflammatory responses in terms of the IFNγ signaling pathway and the eti-
ological link to pathological development of PBC. Furthermore, we present a potential
therapeutic application of luteolin in the treatment of PBC, as well as other Th1-mediated
autoimmune diseases, based on comparison of similar immune responses.
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